Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 11:43 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 121–144 of 717 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Immune Function Clear all
Completed Not applicable Interventional

The Effect of Aerobic Exercise on Cognitive Function and Sleep Quality in Individuals With Multiple Sclerosis

NCT01783665
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
aerobic exercise, home exercise program
Other
Lead sponsor
Catherine Siengsukon, PT, PhD
Other
Eligibility
21 Years to 80 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Aug 28, 2019 · Synced Oct 21, 2026, 11:43 AM EDT
Completed Phase 2 Interventional Results available

Trial to Evaluate the Safety and Immunogenicity of a Modified Vaccinia Ankara (MVA)-Based Anti-Cytomegalovirus (CMV) Vaccine (Triplex®)

NCT05099965
View directory record Official record
Conditions
Cytomegalovirus Infections, HIV Infections, Vaccine
Interventions
CMV-MVA Triplex, Placebo
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 65 Years
Enrollment
94 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
12
States / cities
Birmingham, Alabama • Los Angeles, California • San Diego, California + 9 more
Source: ClinicalTrials.gov public record
Updated Oct 2, 2026 · Synced Oct 21, 2026, 11:43 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Intranasal Insulin for Improving Cognitive Function in Multiple Sclerosis

NCT02988401
View directory record Official record
Conditions
Multiple Sclerosis, Relapsing-Remitting, Multiple Sclerosis, Secondary Progressive, Multiple Sclerosis, Primary Progressive
Interventions
Insulin, Placebo (Sterile diluent)
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 70 Years
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 10, 2023 · Synced Oct 21, 2026, 11:43 AM EDT
Completed Phase 1 Interventional

Cyclophosphamide and Fludarabine to Treat Lupus Nephritis

NCT00001676
View directory record Official record
Conditions
Glomerulonephritis, Lupus Nephritis, Systemic Lupus Erythematosus
Interventions
SQ Fludarabine
Drug
Lead sponsor
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
NIH
Eligibility
Not listed
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2002
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 21, 2026, 11:43 AM EDT
Not listed Not applicable Interventional

Effectiveness of EEG Neurofeedback in Pediatric Occupational Therapy to Improve Executive Functioning

NCT04221620
View directory record Official record
Conditions
Executive Functioning, Pediatric ALL
Interventions
Zengar Electroencephalogram (EEG) Neurofeedback device
Device
Lead sponsor
Northern Arizona University
Other
Eligibility
6 Years to 18 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Prescott, Arizona
Source: ClinicalTrials.gov public record
Updated Jan 9, 2020 · Synced Oct 21, 2026, 11:43 AM EDT
Completed Not applicable Interventional

Effect of Anti-HIV Therapy (HAART) on HIV Levels in the Lungs and on Lung Cell Inflammation in HIV-Infected Patients

NCT00001110
View directory record Official record
Conditions
HIV Infections
Interventions
Bronchoalveolar lavage
Procedure
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2003
U.S. locations
4
States / cities
Indianapolis, Indiana • New York, New York • Cincinnati, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 29, 2013 · Synced Oct 21, 2026, 11:43 AM EDT
Active, not recruiting No phase listed Observational

Post Market Follow-Up Study of the EVOLUTION® Total Knee Arthroplasty System With Cruciate Sacrificing Inserts

NCT02351414
View directory record Official record
Conditions
Joint Disease
Interventions
Total Knee Arthroplasty (EVOLUTION®)
Device
Lead sponsor
MicroPort Orthopedics Inc.
Industry
Eligibility
21 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2028
U.S. locations
1
States / cities
Morton Grove, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 13, 2022 · Synced Oct 21, 2026, 11:43 AM EDT
Completed No phase listed Observational

Sleep, Coping and Executive Functioning in Youth With Type 1 Diabetes

NCT02908555
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
No intervention
Other
Lead sponsor
Yale University
Other
Eligibility
10 Years to 16 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
West Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jul 2, 2018 · Synced Oct 21, 2026, 11:43 AM EDT
Completed Phase 2 Interventional

Study of TNFR:Fc (Enbrel) in the Treatment of Asthma

NCT00001893
View directory record Official record
Conditions
Asthma
Interventions
TNFR:Fc
Drug
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
18 Years to 65 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1999
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 21, 2026, 11:43 AM EDT
Recruiting Not applicable Interventional

Non-chemotherapeutic Interventions for the Improvement of Quality of Life and Immune Function in Patients With Multiple Myeloma

NCT05312255
View directory record Official record
Conditions
Plasma Cell Myeloma, Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma, Smoldering Plasma Cell Myeloma
Interventions
Behavioral Intervention, Beta-Adrenergic Antagonist, Propranolol, Quality-of-Life Assessment, Questionnaire Administration, Resistance Training, Short-Term Fasting
Behavioral · Drug · Other
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
175 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Dec 1, 2025 · Synced Oct 21, 2026, 11:43 AM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Maternal & Offspring Microbiome Study

NCT05123612
View directory record Official record
Conditions
Pregnancy Related, Microbiome, Immune Function, Inflammation
Interventions
Fiber, Fermented Foods
Behavioral
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
135 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2029
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Apr 6, 2026 · Synced Oct 21, 2026, 11:43 AM EDT
Completed Phase 3 Interventional

Study of Eszopiclone Compared to Placebo on Daytime Function in Subjects With Insomnia Related to Rheumatoid Arthritis

NCT00367965
View directory record Official record
Conditions
Insomnia, Arthritis, Rheumatoid
Interventions
Eszopiclone, placebo
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
25 Years to 64 Years
Enrollment
153 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004
U.S. locations
38
States / cities
Huntsville, Alabama • Tucson, Arizona • Santa Maria, California + 35 more
Source: ClinicalTrials.gov public record
Updated Feb 22, 2012 · Synced Oct 21, 2026, 11:43 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Effects of Acipimox on Insulin Action, Vascular Function, and Muscle Function in Type 1 Diabetes

NCT01816165
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Acipimox, Placebo
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
25 Years to 59 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2015
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Jan 21, 2022 · Synced Oct 21, 2026, 11:43 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate ASP0367 in Participants With Mild/Moderate Hepatic Impairment Compared to Participants With Normal Hepatic Function

NCT04942964
View directory record Official record
Conditions
Hepatic Impairment, Healthy Volunteers
Interventions
Bocidelpar
Drug
Lead sponsor
Astellas Pharma Global Development, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
3
States / cities
Miami, Florida • Orlando, Florida • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Oct 21, 2024 · Synced Oct 21, 2026, 11:43 AM EDT
Recruiting Not applicable Interventional

A Novel Combinatory Approach to Maximize Functional Recovery of Learning and Memory in Multiple Sclerosis

NCT06197685
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
The Kessler Foundation modified Story Memory Technique® (KF-mSMT®), Aerobic Exercise Training (AET) plus Virtual Reality (IDEAL), Stretching and Toning (S/T)
Behavioral
Lead sponsor
Kessler Foundation
Other
Eligibility
18 Years to 70 Years
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated Aug 5, 2026 · Synced Oct 21, 2026, 11:43 AM EDT
Completed Early Phase 1 Interventional Results available

Study to Assess Safety and Immune Response of Stage IIB-IV Resected Melanoma After Treatment With MAGE-A3 ASCI

NCT01425749
View directory record Official record
Conditions
Melanoma
Interventions
recMAGE-A3 + AS15 ASCI
Biological
Lead sponsor
Craig L Slingluff, Jr
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Apr 4, 2016 · Synced Oct 21, 2026, 11:43 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

High Intensity Functional Training for Individuals With Neurologic Diagnoses and Their Care Partners

NCT05951985
View directory record Official record
Conditions
Neurologic Disorder, Parkinson Disease, Spinal Cord Injuries, Spina Bifida, Stroke, Poliomyelitis, Multiple Sclerosis, Brain Injuries
Interventions
HIFT
Behavioral
Lead sponsor
Arkansas Colleges of Health Education
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
1
States / cities
Fort Smith, Arkansas
Source: ClinicalTrials.gov public record
Updated Aug 22, 2025 · Synced Oct 21, 2026, 11:43 AM EDT
Completed Not applicable Interventional Results available

Uncontrolled Lower Respiratory Symptoms in the WTC Survivor Program

NCT02024204
View directory record Official record
Conditions
Lung Diseases, Medication Compliance
Interventions
Fluticasone propionate 230mcg for 3 Months, Current Treatment or no treatment, Salmeterol 21mcg for 3 Months
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 75 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 2, 2021 · Synced Oct 21, 2026, 11:43 AM EDT
Terminated Phase 1 Interventional Results available

Fecal Microbiota Transplantation (FMT) of FMP30 in Relapsing-Remitting Multiple Sclerosis

NCT03594487
View directory record Official record
Conditions
Relapsing Remitting Multiple Sclerosis
Interventions
FMP30 Donor Stool, Fecal Microbiota Transplantation (FMT) of FMP30 Donor Stool, Observational Control
Drug · Procedure · Other
Lead sponsor
Jeffrey Gelfand
Other
Eligibility
18 Years to 60 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Feb 3, 2026 · Synced Oct 21, 2026, 11:43 AM EDT
Recruiting Phase 2 Interventional

Regenerative Medicine to Restore Hematopoiesis and Immune Function in Immunodeficiencies and Inherited Bone Marrow Failures

NCT04232085
View directory record Official record
Conditions
Primary Immune Deficiency Disorder, Immune Deficiency Disease, Bone Marrow Failure, Short Telomere Length, Fanconi Anemia, Non Fanconi DNA-DSB Repair Disorder, Hoyeraal-Hreidarsson Syndrome, Dyskeratosis Congenita, Telomere Biology Disorder, Short Telomere Syndrome
Interventions
Alemtuzumab, Fludarabine, Melphalan, Low Dose Total Body Irradiation, Cyclophosphamide, Tacrolimus, Mycophenolate Mofetil
Drug · Radiation
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
4 Months to 50 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2028
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 28, 2025 · Synced Oct 21, 2026, 11:43 AM EDT
Not listed No phase listed Observational

Developing a Functional Cure for HIV Disease: Clinical Specimen Collection From HIV Positive Individuals

NCT03215004
View directory record Official record
Conditions
HIV Infections
Interventions
Not listed
Lead sponsor
American Gene Technologies International Inc.
Industry
Eligibility
18 Years to 60 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
2
States / cities
Washington D.C., District of Columbia • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 16, 2020 · Synced Oct 21, 2026, 11:43 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

CAPABLE Family Pilot - Adapting CAPABLE for Older Adults With Mild Cognitive Impairment (MCI)/Early Stage Dementia and Their Care Partners

NCT05187117
View directory record Official record
Conditions
Dementia, Mild, Mild Cognitive Impairment, Disability Physical, Impairment, Cognitive, Caregiver Burden, Quality of Life, Depression
Interventions
CAPABLE Family - Open Label Pilot, CAPABLE Family - Randomized Control Trial
Behavioral
Lead sponsor
Johns Hopkins University
Other
Eligibility
60 Years and older
Enrollment
74 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 17, 2024 · Synced Oct 21, 2026, 11:43 AM EDT
Completed Phase 1 Interventional

Phase 1 Study of BAY1905254 - An Early Clinical Research Study to Evaluate a New Drug Called Bapotulimab (BAY1905254) in the Expansion Cohort in Combination With Pembrolizumab in Head and Neck Cancer That Has Returned or is Discovered to be Metastatic and is Expressing PDL1.

NCT03666273
View directory record Official record
Conditions
Advanced Solid Tumor, Head and Neck Squamous Cell Carcinoma
Interventions
Bapotulimab (BAY1905254), Bapotulimab (BAY1905254) + Pembrolizumab (KEYTRUDA®)
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
8
States / cities
Tucson, Arizona • New Haven, Connecticut • Chicago, Illinois + 5 more
Source: ClinicalTrials.gov public record
Updated May 28, 2024 · Synced Oct 21, 2026, 11:43 AM EDT
Not listed Not applicable Interventional

Vitamin D in Pediatric Asthma: a Randomized Controlled Open-label Pilot Trial

NCT02054975
View directory record Official record
Conditions
Asthma, Vitamin D Deficiency
Interventions
Vitamin D2 + vitamin D3, Vitamin D3
Drug
Lead sponsor
Nationwide Children's Hospital
Other
Eligibility
8 Years to 17 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 8, 2015 · Synced Oct 21, 2026, 11:43 AM EDT